Dear All (and with thanks to Damiano for taking the lead on this newsletter): In advance of Italy assuming the G7 Presidency for 2024, The European House – Ambrosetti (an Italian think tank and management consulting firm) published a new report on 15 November 2023 entitled “Value and sustainability of antibiotics as essential tools for the healthcare
Dear All (and with thanks to Kevin for co-authoring), In a clear and compelling policy paper, a dozen of the DRIVE-AB alumni have proposed a concept for a pan-EU/EEA Pull Incentive. To follow the plot, here are the key points as a refresh: To date, the only strong, active Pull model is the UK NHS project that
Note: Be sure to take advantage of the BARDA Industry Day(s) event that occurs Monday-Tuesday of this coming week … see newsletter and forward calendar for details. Dear All, In what could be called Part 2 of Excellent 2023 ASM/ESCMID Talks (read the newsletter on Jen Cohen’s talk on how manufacturing underpins both access and
This newsletter is the first of a series — here are the links to Part 2, Part 3, Part 4, and Part 5. Dear All, Today’s theme is a 3-part journey that could be subtitled “Many are called, but few are chosen,” or “It’s easy to kill bacteria — steam, fire, and bleach are consistently effective —
Dear All, WHO have just released a 2024 update to their 2017 (bacterial) Priority Pathogen List (PPL)! Here are the links you need: The WHO 2024 PPL. WHO’s webpage about the 2024 PPL. A PowerPoint (.pptx) deck (and there is also a .pdf version) summarizing the new PPL and all prior PPLs. 22 May 2024 post-newsletter
Dear All, As you may remember, last fall I wrote a newsletter about ATMF’s 3rd update to the AMR Benchmark series. You are encouraged to read the report but in brief, the key messages are (i) the pipeline is small with most innovation coming from small biotech, (ii) stewardship and access planning are increasingly seen (but
Dear All, NIAID and RTI International have recently announced the initiation of CC4CARB Chemistry Center for Combating Antibiotic Resistance). In brief, CC4CARB synthesizes compound libraries (free of charge!) based on scaffolds that you propose The focus is on creating novel chemical matter that might have antibacterial activity (there appears to be a focus on Gram-negatives, but there
Dear All, IDSA (Infectious Diseases Society of America) have today released an eagerly awaited new guidance document on treating infections due to resistant Gram-negative bacteria (link). 8 Apr 2021 update: IDSA have published an updated version of this document. It excellent to see IDSA working steadily to provide up-to-the-minute advice! 24 Nov 2021 update: IDSA
Dear All (and with thanks to Kevin for leading the charge on this newsletter), While listening to last week’s BEAM-sponsored AMR Conference (really a wonderful conference, thank you Team BEAM, go here to listen to the sessions), we tumbled onto a really, really disturbing trend: New antibiotics are not being registered or sold in Europe in
Dear All (lots and lots of wonkish detail here, be sure your blood caffeine level is adequate!), During the 24-28 Aug 2020 BEAM Alliance-sponsored AMR Conference (go here or see below my signature for more), I had the opportunity on 27 August to chat with Sumati Nambiar (FDA) and Marco Cavaleri (EMA) about ongoing regulatory activities. The